The Smoking Cessation Center has multiple, ongoing research studies primarily investigating new medications for treatment of tobacco dependence. Here are our current studies followed by a link to the Research Study Archives.
Clinical Trials Recruitment Line: 503-494-0503
Active Trial: Open to Enrollment:
- 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial with 40-Week Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate for Smoking Cessation in Patients with Mild-to-Moderate Chronic Obstructive Pulmonary Disease. Pfizer Inc. D. Gonzales, Principal Investigator, C. Markin, Co-Principal Investigator.
Active Trial: Closed to Enrollment:
- Phase 2, Multi-center, Randomized, Double-Blinded, Placebo-controlled Study to Assess Efficacy of 3'-aminomethylnicotine- P. aeruginosa r-Exoprotein A Conjugate Vaccine (nicVAX TM ) in Smokers Who Want to Quit Smoking. Nabi Biopharmaceuticals and National Institutes of Health;. D. Gonzales, Principal Investigator, C. Markin, Co-Principal Investigator.
- Phase IIa, randomized, placebo-controlled study of the safety, tolerability and efficacy of ADX10061 for smoking cessation. Addex Pharmaceuticals. D. Gonzales, Principal Investigator, C. Markin, Co-Principal Investigator.